Is Pyxis Oncology going out of business?

Pyxis Oncology, Inc. (PYXS) Fundamentals

A quick summary of the latest filed figures while the full analysis loads.

Pyxis Oncology, Inc. (PYXS) scores 20 out of 100 on fundamentals, Distressed / Caution, based on SEC filing data.

Leading signal: FCF margin: -458.30%

Five questions, kept separate

Survival - Critical

3-5 mo of estimated runway from 2026-06-30, based on $18.9M of cash and short-term investments against $63.5M of annual burn.

Business quality - Pre-commercial

Operating margins cannot grade a pipeline; Survival and clinical evidence remain the relevant lenses here.

Trajectory - Clinical progress unavailable

Fundamentals can show funding and burn, but not whether the clinical pipeline is advancing.

Valuation - Demanding

-7.8% net-cash backing support a demanding pre-commercial Valuation assessment.

Event risk - Evidence unavailable

No active asserted adverse event was found in the available filing evidence. The filing evidence is stale or incomplete, so this is not proof of absence.

What the rules read

• FCF margin: -458.30%
• Debt / Equity: -0.09x (Net Cash)
• ROIC: -311.65%
• Cash Runway (years): 0.30y
• Return on Assets: -144.97%
• Price / Sales: 20.2x (see Valuation)
• Price / Earnings: Unprofitable (see Valuation)
• Operating leverage: -736.0%
• Shares dilution YoY: 3.59% (YoY)
• Effective Tax Rate: 0.00% (loss-making)

Read from filings through 2026-08-13.

Price as of 2026-09-07.